| Autor: |
Elgharably, A, Gomaa, AI, Crossey, M, Norsworthy, P, Waked, I, Taylor-Robinson, SD |
| Přispěvatelé: |
Wellcome Trust, British Council (UK) |
| Rok vydání: |
2016 |
| Předmět: |
|
| Popis: |
Hepatitis C viral infection is endemic in Egypt with the highest prevalence rate in the world. It is widely accepted that the implementation of mass population anti-schistosomal treatment involving administration of tartar emetic injections (between the 1950s to the 1980s) led to widespread infection. What is less well known, however, is that these schemes were implemented by the Egyptian Ministry of Health on the advice of the World Health Organisation. There has been a spectrum of treatments to target the public health disaster represented by the hepatitis C problem in Egypt: from the use of pegylated-Interferon to the recent use of direct acting antiviral drugs. Some new treatments have shown greater than 90% efficacy. However, cost is a key barrier to access of these new medicines. This is coupled with a growing population, limited resources and a lack of infection control practices which mean Egypt still faces significant disease control issues today. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
